Pharmaceuticals company Neuland Laboratories announced Q3FY25 results Total Income: Rs 401.9 crore (1.8% growth YoY from Rs 394.9 crore). EBITDA: Rs 90.3 crore (decline of 26.4% YoY from Rs 122.7 crore). EBITDA Margin: 22.5% (decline of 860 bps YoY from 31.1%). PAT: Rs 101.4 crore (growth of 25.6% YoY from Rs 80.7 crore). PAT Margin: 25.2% (increase of 480 bps YoY from 20.4%). EPS (Basic): Rs 79.0 (growth of 25.6% YoY from Rs 62.9). Sucheth Davuluri, Vice-Chairman & Chief Executive Officer of the Company said: “We saw marginal topline growth this quarter as compared to Q3FY24. Nevertheless, these results align with our initial outlook at the start of the year regarding our expectations for FY25. We are steadily advancing our strategic initiatives and remain optimistic about achieving sustainable long-term growth through acquiring new customers, enhancing our expertise, expanding our capacity flexibly, and refining our processes.” Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “This quarter’s revenues were driven by several important molecules in the commercial CMS and GDS segments. We expect the recently commercialized molecules to scale even as we are on track to enhance our manufacturing capacity. There is good traction from our existing customers reverting for multiple projects as well as fresh interest from a range of new customeRs We are seeing increased interest in peptides leading to our recent decision to invest in a larger capacity. Overall, we are confident on the business momentum for the medium as well as long term.” Result PDF